HIV PrEP available on PBS in Australia from 1 April / Links to Clinical Resources

Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM), 21 March 2018

ASHM congratulates the Federal Health Minister, the Hon. Greg Hunt’s announcement of a landmark in HIV prevention to approve HIV-prevention drugs – tenofovir with emtricitabine, known as PrEP – on the Pharmaceutical Benefits Scheme from 1 April, thereby providing broader access for any doctor or general practitioner to be able prescribe PrEP to an Australian resident who holds a current Medicare card.

“The public health benefits are clear, undeniable and transformative benefiting individuals at medium- to high-risk of HIV infection and towards driving a substantial reduction in HIV transmissions in Australia,” said ASHM President, Associate Professor Bloch.

Access Links to Clinical Resources supporting the HIV workforce

  • The definitions of risk for HIV, guidelines and procedures for the appropriate administration and monitoring of PrEP can be found here: ASHM HIV pre-exposure prophylaxis: clinical guidelines
  • The Australian Federation of AIDS Organisations (AFAO) and ASHM have produced a PrEP Fact Sheet to assist PrEP users and people with an interest in using PrEP to understand what subsidised access to PrEP through the PBS means. Access the factsheet here
  • ASHM continues to support the workforce to ensure access to PrEP and best practice in guidelines, training and resources. Access information here
  • The Pharmaceutical Society of Australia has a range of training to support pharmacists in preparing for PrEP on the PBS: www.psa.org.au

 

Push to dispel myths about long-lasting contraception

Guardian Australia, Tuesday 26 September 2017 

Misplaced concerns and myths about long-acting reversible contraceptives have prompted medical experts to release Australia’s first consensus statement, saying they are more reliable and effective than condoms or the pill.

Despite their safety, efficacy and widespread use internationally, the uptake of long-acting reversible contraceptives (LARCs) is low in Australia. On Tuesday the Australian Healthcare and Hospitals Association released a consensus statement – endorsed by 18 agencies, including SHINE SA – on the use of LARCs.

Australia leads the world in hepatitis C treatment – what’s behind its success?

The Conversation, July 31, 2017 4.05pm AEST

The World Health Organisation recently set ambitious goals for the “elimination of hepatitis C as a major public health threat”. These included having 80% of people treated and an 80% reduction in the spread of the virus by 2030. Given there are around 70 million people infected with hep C worldwide, only 20% diagnosed, and no effective vaccine, the task ahead is enormous.

But Australia is impressively heading towards these targets and may present a model for other countries to adopt. A recent report by the Kirby Institute estimated Australia was on track to eliminate hepatitis C by 2026 – four years earlier than the WHO goal.

Latest research shows Australia on track to cure Hepatitis C

Kirby Institute/UNSW – 21 February 2017

More Australians were treated for their hepatitis C infection in the first year new generation hepatitis C regimens were made available on the Pharmaceutical Benefits Schemes than in the past decade, according to a new report released today by the Kirby Institute at UNSW Sydney.

 

VAC announces $100,000 for PREPX trial [for HIV prevention]

Gay News Network, Wednesday 18 January 2017

The Victorian AIDS Council has announced it will give an additional $100,000 to the PrEPX trial to fund access to pre-exposure prophylaxis for HIV (PrEP) for 600 Victorians at risk.

VAC’s announcement comes months after PrEPX reached capacity for men living in
metropolitan Melbourne. The VAC said there is already a substantial waiting list for those wishing to access PrEP as part of the trial.

Breaking news: SA announces HIV prevention drug trial

Jay Weatherill MP, Nat Cook MP, Wednesday, November 29, 2016

South Australians at high risk of contracting HIV will have access to the latest preventative technology study, as part of a State Government commitment announced today.

Pre-exposure prophylaxis or PrEP is the latest prevention therapy in the fight against HIV. Under a PrEP access trial, eligible South Australians who don’t have HIV and who are at high risk of acquiring HIV may be prescribed a daily oral pill which, when taken consistently, has been shown to be effective in preventing HIV.

South Australia will commence negotiations with other states currently leading PrEP access trials.

Read more hiv-prevention-drug-trial